Erdafitinib in BCG-treated high risk non-muscle invasive bladder cancer

James W.F. Catto, Ben Tran, Morgan Roupret, Juergen E. Gschwend, Yohann Loriot, Hiroyuki Nishiyama, Joan P. Redorta, Siamak Daneshmand, Syed A. Hussain, Hernan J Cutuli, Giuseppe Procopio, Valentina Guadalupi, Nikhil Vasdev, Vahid Naini, Lauren Crow, Spyros Triantos, Mahadi Baig, Gary D. Steinberg

Research output: Contribution to journalArticlepeer-review

1 Downloads (Pure)

Abstract

Background: Treatment options are limited for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) with disease recurrence after bacillus Calmette–Guérin (BCG) treatment and who are ineligible for/refuse radical cystectomy. FGFR alterations are commonly detected in NMIBC. We evaluated the activity of oral erdafitinib, a selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, versus intravesical chemotherapy in patients with high-risk NMIBC and select FGFR3/2 alterations following recurrence after BCG treatment. Patients and methods: Patients aged ≥18 years with recurrent, BCG-treated, papillary-only high-risk NMIBC (high-grade Ta/T1) and select FGFR alterations refusing or ineligible for radical cystectomy were randomized to 6 mg daily oral erdafitinib or investigator's choice of intravesical chemotherapy (mitomycin C or gemcitabine). The primary endpoint was recurrence-free survival (RFS). The key secondary endpoint was safety. Results: Study enrollment was discontinued due to slow accrual. Seventy-three patients were randomized 2: 1 to erdafitinib (n = 49) and chemotherapy (n = 24). Median follow-up for RFS was 13.4 months for both groups. Median RFS was not reached for erdafitinib [95% confidence interval (CI) 16.9 months-not estimable] and was 11.6 months (95% CI 6.4-20.1 months) for chemotherapy, with an estimated hazard ratio of 0.28 (95% CI 0.1-0.6; nominal P value = 0.0008). In this population, safety results were generally consistent with known profiles for erdafitinib and chemotherapy. Conclusions: Erdafitinib prolonged RFS compared with intravesical chemotherapy in patients with papillary-only, high-risk NMIBC harboring FGFR alterations who had disease recurrence after BCG therapy and refused or were ineligible for radical cystectomy.

Original languageEnglish
Pages (from-to)98-106
Number of pages9
JournalAnnals of Oncology
Volume35
Issue number1
Early online date21 Oct 2023
DOIs
Publication statusPublished - 30 Jan 2024

Keywords

  • FGFR
  • erdafitinib
  • intravesical chemotherapy
  • non-muscle-invasive bladder cancer
  • recurrence-free survival
  • safety

Fingerprint

Dive into the research topics of 'Erdafitinib in BCG-treated high risk non-muscle invasive bladder cancer'. Together they form a unique fingerprint.

Cite this